CN1308086A - 抗菌/抗内毒素模拟肽、其制备方法及应用 - Google Patents
抗菌/抗内毒素模拟肽、其制备方法及应用 Download PDFInfo
- Publication number
- CN1308086A CN1308086A CN 01104591 CN01104591A CN1308086A CN 1308086 A CN1308086 A CN 1308086A CN 01104591 CN01104591 CN 01104591 CN 01104591 A CN01104591 A CN 01104591A CN 1308086 A CN1308086 A CN 1308086A
- Authority
- CN
- China
- Prior art keywords
- peptide
- antiendotoxic
- antibiotic
- mimic
- bpi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 193
- 230000003278 mimic effect Effects 0.000 title claims abstract description 91
- 230000001986 anti-endotoxic effect Effects 0.000 title claims abstract description 89
- 230000003115 biocidal effect Effects 0.000 title claims description 82
- 238000002360 preparation method Methods 0.000 title claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 44
- 241000894006 Bacteria Species 0.000 claims abstract description 36
- 229920001184 polypeptide Polymers 0.000 claims abstract description 33
- 230000000694 effects Effects 0.000 claims abstract description 19
- 208000037487 Endotoxemia Diseases 0.000 claims abstract description 17
- 238000013461 design Methods 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 10
- 238000005094 computer simulation Methods 0.000 claims abstract description 9
- 239000007790 solid phase Substances 0.000 claims abstract description 7
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 6
- 239000002158 endotoxin Substances 0.000 claims description 39
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 33
- 229920005989 resin Polymers 0.000 claims description 27
- 239000011347 resin Substances 0.000 claims description 27
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 24
- 239000000523 sample Substances 0.000 claims description 17
- 235000001014 amino acid Nutrition 0.000 claims description 15
- 235000018102 proteins Nutrition 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 239000003053 toxin Substances 0.000 claims description 15
- 231100000765 toxin Toxicity 0.000 claims description 15
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 239000012071 phase Substances 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- 230000002209 hydrophobic effect Effects 0.000 claims description 9
- 230000003834 intracellular effect Effects 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 238000005421 electrostatic potential Methods 0.000 claims description 7
- 238000007710 freezing Methods 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
- 230000008827 biological function Effects 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 230000008014 freezing Effects 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 239000007821 HATU Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000010189 synthetic method Methods 0.000 claims description 5
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 239000006166 lysate Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 229920000361 Poly(styrene)-block-poly(ethylene glycol) Polymers 0.000 claims description 3
- 229960000583 acetic acid Drugs 0.000 claims description 3
- -1 azepine benzo triazole methyl urea hexafluorophosphate Chemical compound 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 230000000903 blocking effect Effects 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 238000005336 cracking Methods 0.000 claims description 3
- 230000009881 electrostatic interaction Effects 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000012362 glacial acetic acid Substances 0.000 claims description 3
- 238000005374 membrane filtration Methods 0.000 claims description 3
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 239000012488 sample solution Substances 0.000 claims description 3
- 229920003002 synthetic resin Polymers 0.000 claims description 3
- 239000000057 synthetic resin Substances 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 2
- 230000004087 circulation Effects 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 238000009826 distribution Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 238000012900 molecular simulation Methods 0.000 claims description 2
- 235000000177 Indigofera tinctoria Nutrition 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229940097275 indigo Drugs 0.000 claims 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 claims 1
- 238000004458 analytical method Methods 0.000 abstract description 13
- 230000003472 neutralizing effect Effects 0.000 abstract description 5
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 4
- 208000015181 infectious disease Diseases 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 102000052586 bactericidal permeability increasing protein Human genes 0.000 description 57
- 108010032816 bactericidal permeability increasing protein Proteins 0.000 description 57
- 229920006008 lipopolysaccharide Polymers 0.000 description 33
- 241001465754 Metazoa Species 0.000 description 23
- 102100040247 Tumor necrosis factor Human genes 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 102000004889 Interleukin-6 Human genes 0.000 description 14
- 108090001005 Interleukin-6 Proteins 0.000 description 14
- 241000700159 Rattus Species 0.000 description 14
- 229940100601 interleukin-6 Drugs 0.000 description 14
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 230000000968 intestinal effect Effects 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 206010040047 Sepsis Diseases 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000000855 fungicidal effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 102000018594 Tumour necrosis factor Human genes 0.000 description 6
- 108050007852 Tumour necrosis factor Proteins 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000012916 structural analysis Methods 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 101000648290 Rattus norvegicus Tumor necrosis factor Proteins 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000005611 electricity Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000000452 restraining effect Effects 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 238000010205 computational analysis Methods 0.000 description 3
- 230000000249 desinfective effect Effects 0.000 description 3
- 231100000284 endotoxic Toxicity 0.000 description 3
- 230000002346 endotoxic effect Effects 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 108010072542 endotoxin binding proteins Proteins 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102100033735 Bactericidal permeability-increasing protein Human genes 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 241000148131 Colibacter Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 101000871785 Homo sapiens Bactericidal permeability-increasing protein Proteins 0.000 description 1
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000003867 Phospholipid Transfer Proteins Human genes 0.000 description 1
- 108090000216 Phospholipid Transfer Proteins Proteins 0.000 description 1
- 102100022428 Phospholipid transfer protein Human genes 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101001076459 Rattus norvegicus Interleukin-6 Proteins 0.000 description 1
- 241000190932 Rhodopseudomonas Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 208000006666 Shwartzman Phenomenon Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000239222 Tachypleus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
管号 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 对照管 |
菌液(105cfu/ml)(ml) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
模拟肽样品(μg/ml) | 128 | 64 | 32 | 16 | 8 | 4 | 2 | 1 | 0.5 | 0.25 | 0.125 |
时间(小时) | 对照组 | 存活率(%) | |||
9901315 | 9901289 | 9901501 | 9901286 | ||
1.02.03.04.05.0 | 10010067200 | 1001001009080 | 10010010010090 | 10010010010090 | 100100100100100 |
分组 | 剂 量(mg/kg) | 实验动物(只) | 死亡动物(只) | P值 |
LPS | - | 10 | 10 | |
地塞米松 | 10 | 10 | 2 | <0.01 |
BNEP2001695 | 5 | 10 | 0 | <0.01 |
BNEP9801287 | 5 | 10 | 1 | <0.01 |
BNEP9901317 | 5 | 10 | 0 | <0.01 |
BNEP9901315 | 5 | 10 | 5 | >0.05 |
BMEP9801161 | 5 | 10 | 4 | >0.05 |
BNEP9901321 | 5 | 10 | 1 | <0.01 |
BNEP9801286 | 5 | 10 | 3 | <0.05 |
BNEP9801174 | 5 | 10 | 6 | >0.05 |
BNEP9801013 | 5 | 10 | 1 | <0.01 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB011045914A CN1148379C (zh) | 2001-02-14 | 2001-02-14 | 抗菌/抗内毒素模拟肽、其制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB011045914A CN1148379C (zh) | 2001-02-14 | 2001-02-14 | 抗菌/抗内毒素模拟肽、其制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1308086A true CN1308086A (zh) | 2001-08-15 |
CN1148379C CN1148379C (zh) | 2004-05-05 |
Family
ID=4653970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB011045914A Expired - Fee Related CN1148379C (zh) | 2001-02-14 | 2001-02-14 | 抗菌/抗内毒素模拟肽、其制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1148379C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101851276A (zh) * | 2010-04-28 | 2010-10-06 | 东北农业大学 | 一种抗菌肽的制备方法及活性检测 |
CN101402676B (zh) * | 2008-11-12 | 2011-10-05 | 西南大学 | 聚乙二醇类修饰的中和内毒素多肽及其制备方法和应用 |
-
2001
- 2001-02-14 CN CNB011045914A patent/CN1148379C/zh not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101402676B (zh) * | 2008-11-12 | 2011-10-05 | 西南大学 | 聚乙二醇类修饰的中和内毒素多肽及其制备方法和应用 |
CN101851276A (zh) * | 2010-04-28 | 2010-10-06 | 东北农业大学 | 一种抗菌肽的制备方法及活性检测 |
CN101851276B (zh) * | 2010-04-28 | 2012-02-29 | 东北农业大学 | 一种抗菌肽的制备方法及活性检测 |
Also Published As
Publication number | Publication date |
---|---|
CN1148379C (zh) | 2004-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
David | Towards a rational development of anti‐endotoxin agents: novel approaches to sequestration of bacterial endotoxins with small molecules | |
Domadia et al. | Structure, interactions, and antibacterial activities of MSI-594 derived mutant peptide MSI-594F5A in lipopolysaccharide micelles: role of the helical hairpin conformation in outer-membrane permeabilization | |
Kumar et al. | Aurein-derived antimicrobial peptides formulated with pegylated phospholipid micelles to target methicillin-resistant Staphylococcus aureus skin infections | |
CN101155825B (zh) | 抗微生物六肽 | |
Sharon et al. | 2D-NMR and ATR-FTIR study of the structure of a cell-selective diastereomer of melittin and its orientation in phospholipids | |
Feigman et al. | Synthetic immunotherapeutics against Gram-negative pathogens | |
CN109988225B (zh) | 具抗菌活性的多肽及其应用 | |
Brunetti et al. | Immunomodulatory and anti-inflammatory activity in vitro and in vivo of a novel antimicrobial candidate | |
EP0988314B1 (en) | Synthetic peptides with antimicrobial and endotoxin neutralizing properties for management of the sepsis syndrome | |
CN1638794A (zh) | 用于免疫受损人群的糖结合物疫苗 | |
JP2002508767A (ja) | C5a受容体およびGタンパク質結合受容体の環状アゴニストおよびアンタゴニスト | |
Domeneghetti et al. | Structural and antimicrobial features of peptides related to Myticin C, a special defense molecule from the Mediterranean mussel Mytilus galloprovincialis | |
CN106232616B (zh) | 两亲性合成抗菌肽、其药物组合物及其用途 | |
CN117586352B (zh) | 一种基于宽体金线蛭唾液腺的抗菌多肽aph220及其应用 | |
CN106543271B (zh) | 抗耐药性感染多肽Cbf-14-2及其用途 | |
Álvarez et al. | Immune modulation ability of hepcidin from teleost fish | |
Jensen et al. | Novel cyclic lipopeptide antibiotics: effects of acyl chain length and position | |
CN110804091B (zh) | 一种人肠道防御素5衍生线性多肽及其制备方法和应用 | |
CN107454846A (zh) | 修饰的肽及其治疗慢性炎性疾病的用途 | |
CN101054408A (zh) | 家蝇分泌型抗菌肽的分离方法及其产品和应用 | |
Fabisiak et al. | Anti-inflammatory and antibacterial effects of human cathelicidin active fragment KR-12 in the mouse models of colitis: a novel potential therapy of inflammatory bowel diseases | |
CN117430672A (zh) | 一种新型抗菌肽及其药物组合物 | |
CN1218057A (zh) | 鲎属抗lps因子的肽的新免疫学活性 | |
CN1308086A (zh) | 抗菌/抗内毒素模拟肽、其制备方法及应用 | |
Zhang et al. | Development of a highly efficient hybrid peptide that increases immunomodulatory activity via the TLR4-mediated nuclear factor-κB Signaling Pathway |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY M Free format text: FORMER OWNER: ZHENG JIANG Effective date: 20040702 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20040702 Address after: Chongqing city Shapingba street 400038 gaotanyan No. 30 Patentee after: No.1 Attached Hospital, No.3 Military Medical College PLA. Address before: The 400038 week high street is Shapingba District of Chongqing City No. 30 red rock comprehensive experimental research center of Southwest Hospital Patentee before: Zheng Jiang |
|
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |